Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02017964 · OUTCOME

Progression-free Survival (PFS)

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma · Source last updated 2023-01-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent probability
Interval / dispersion
95% Confidence Interval
Time frame
2 years from diagnosis

What was measured

Progression-free survival (PFS) is defined as the time interval from diagnosis to the earliest of disease progression/recurrence or death from any cause, or to the date of last follow-up for patients without events. PFS was estimated using the method of Kaplan and Meier. 2-year estimates are reported with 95% CI's.

Analysis population: 26 patients were enrolled on the protocol, but 1 was deemed ineligible. The ineligible patient was excluded from all analyses.

Groups in this outcome

All Eligible Patients (Combination Chemotherapy)

All eligible patients enrolled on the study

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Eligible Patients (Combination Chemotherapy)25

Reported measurements

Source class 1
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Eligible Patients (Combination Chemotherapy)52.0Not reported32.471.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        32.4
        upper Limit
        71.6
        value
        52.0
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Progression-free survival (PFS) is defined as the time interval from diagnosis to the earliest of disease progression/recurrence or death from any cause, or to the date of last follow-up for patients without events. PFS was estimated using the method of Kaplan and Meier. 2-year estimates are reported with 95% CI's.
dispersion Type
95% Confidence Interval
groups
  1. description
    All eligible patients enrolled on the study
    id
    OG000
    title
    All Eligible Patients (Combination Chemotherapy)
param Type
NUMBER
population Description
26 patients were enrolled on the protocol, but 1 was deemed ineligible. The ineligible patient was excluded from all analyses.
reporting Status
POSTED
time Frame
2 years from diagnosis
title
Progression-free Survival (PFS)
type
PRIMARY
unit Of Measure
percent probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice